Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease
about
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directionsHIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbiditiesModeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia.Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in childrenAberrant monocyte responses predict and characterize dengue virus infection in individuals with severe disease.Robust clinical outcome prediction based on Bayesian analysis of transcriptional profiles and prior causal networksSerological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota.Gut microbes, diet, and cancer.Human schistosomiasis is associated with endotoxemia and Toll-like receptor 2- and 4-bearing B cells.Monocyte human leukocyte antigen-DR expression-a tool to distinguish intestinal bacterial infections from inflammatory bowel disease?Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.Endotoxin neutralization as a biomonitor for inflammatory bowel disease.The gut microbiota and the liver: implications for clinical practice.The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model.Markers of systemic exposures to products of intestinal bacteria in a dietary intervention study.Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.Gut commensal microbes do not represent a dominant antigenic source for continuous CD4+ T-cell activation during HIV-1 infection.Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome.CD14(+) macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide.An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's diseaseExperimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection.Lipopolysaccharide binding protein is down-regulated during acute liver failure.Microbial translocation across the GI tractLipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14From therapy to experimental model: a hundred years of endotoxin administration to human subjects.Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.Application of prodrugs to inflammatory diseases of the gut.Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.New biomarkers of Crohn's disease: serum biomarkers and development of diagnostic tools.Hyperactivated B cells in human inflammatory bowel disease.Role of gut microbiota in liver diseases.Bacterial induction of proinflammatory cytokines in inflammatory bowel disease.Role of the gut in visceral fat inflammation and metabolic disorders.Microbial translocation in HIV infection: causes, consequences and treatment opportunities.Reliability of plasma lipopolysaccharide-binding protein (LBP) from repeated measures in healthy adultsStress induces endotoxemia and low-grade inflammation by increasing barrier permeability.Chasing a ghost?--Issues with the determination of circulating levels of endotoxin in human blood.Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis.IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease.
P2860
Q26745700-DBEE0957-9138-4007-B0C5-F6B46623297DQ27015965-465EA35C-2C48-4295-985E-CC26229603A4Q30846620-919B0108-B97E-44FC-B800-82DE759B812DQ33534036-D7911A99-64A5-4340-A7AC-519EA3C5F57BQ33750037-5F7D21CC-3A0F-4104-89A0-E6CE32747D00Q33760414-FA1B4B4C-C7B6-4249-B0FF-9949F68CA490Q33761406-06B8CAC8-3A96-43D5-A563-F55AC65C8E41Q33940769-6A24CD99-D131-4BF9-9208-09878E992641Q34000541-6841BBC3-8536-4C26-8E7F-7E52F9140DCCQ34531341-28368968-7E1B-4E04-8D7F-F3C438FFB4E8Q34568558-64E9E2BE-DEE5-41EB-88D0-B7BE1A4A0D0FQ34640072-46CBB2D4-8CAD-4599-9428-2C4ACEAD468AQ34797504-FE4BF9F3-B933-49D8-97B5-4DAA2A9461E8Q35019661-3866D59C-01A8-4A1F-935C-70289608B2F1Q35610662-08AEFED4-A106-4149-B38F-57D0B4ED75B2Q35611937-F5B8A2F7-22F0-4F3F-BF4A-BE2B4AEE5B4BQ35694271-678123A5-9620-40C8-8AEC-FB978537AFAEQ35765806-DDA2B288-8BEE-4DC6-B455-79624881ACD7Q35781494-A380CF32-AB31-46C9-8361-3B03D796E81BQ35810983-C1822050-0BB8-43BE-9BEC-3DC0186445DAQ35846531-C9E5A69A-C973-439A-AE2F-9705A2E7392AQ35982025-B9EE53F7-EDA6-4076-811A-8627DAF9401FQ36406505-09F11E0D-4831-475B-8F50-21E181CCA885Q36441742-1A0BF6E5-FCD9-4D7A-BA1D-404322360335Q36582869-38AA2EAB-84EB-4E3E-B71F-EF31D6FC60C3Q36994694-3D908CF4-638B-48E3-BB05-B8F3A489926AQ37002388-69351238-9F4D-402B-B790-070C2050DB81Q37096512-DD73EEF8-79E2-4368-984E-91ED6BBB52CBQ37170549-7BB3596F-4488-4455-80FE-8D9B35D3FB4EQ37206175-961E7167-44D7-4EA8-80E5-789898196327Q37486515-DAFBF24F-F2D1-4F9B-BFAA-22FC2B480060Q37488165-C90B7F6D-1A13-47F4-A623-5132E2FD1678Q37789694-378BAD38-F62A-4530-B3A6-DFE65B580A16Q37924590-361C218D-8199-46B3-9A1A-8BC5239EBCA6Q38034068-CD81E03E-8C5C-46A6-A9B9-03EF8B9669A3Q38379385-01AC0EBB-7A3D-4339-A38A-4FBEF6A6DF20Q38510131-D6CF520C-24A8-4C6B-AC77-DB18FFD35E42Q38687215-C13D1DD6-BDA7-4253-A6E9-D4F6B3F3CD93Q39906288-C5C9C351-9745-4DE8-8F09-99B5F3A16C3EQ40147698-40CD5E91-6271-40F0-B361-9E2868137EF3
P2860
Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease
description
im März 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2007
@uk
name
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@en
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@nl
type
label
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@en
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@nl
prefLabel
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@en
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@nl
P2093
P2860
P356
P1476
Serum lipopolysaccharide-bindi ...... ith inflammatory bowel disease
@en
P2093
Agustín Albillos Martínez
Antonio López San Román
Antonio de la Hera Martínez
Eduardo Albéniz Arbizu
Eduardo Ripoll Sevillano
Óscar Pastor Rojo
P2860
P304
P356
10.1002/IBD.20019
P577
2007-03-01T00:00:00Z